

Sanofi Pasteur:

95 Years of Vaccine Manufacturing in



Sanofi Pasteur's heritage



Overview of sanofi pasteur in Canada



Two Locations

Connaught Campus: 1,040 employees

Connaught Campus

(located at Steeles & Dufferin)



Sunnybrook Campus:60 research scientists



Sunnybrook Campus

(Sunnybrook & Women's College Health Sciences Centre)



Overview of sanofi pasteur in Canada



| | Research & Development: |
|--|---|
| | 250 employees |
| | Research, Development, Clinical, Medical and Regulatory |
| | Industrial Operations: |
| | 600 employees – uniquely skilled and highly educated workforce |
| | 200 million doses/year to international markets |
| | Commercial Operations: |
| | ☐ 150 employees – Sales, Marketing, Public Policy, and Legal |
| | 25 products – 14 million doses of vaccines/year in Canada |



sanofi pasteur Canada Ltd.



History:

- Originated as Connaught Laboratories in 1914 at the Hygiene Department of U of T
- Opened manufacturing facility in 1917 on 150 acre farm at Steeles & Dufferin

Dr. John Fitzgerald (Canadian Medical Hall of Fame) was the first director





sanofi pasteur Canada Ltd.



History:

- Originated as Connaught Laboratories in 1914 at the Hygiene Department of U of T
- Opened manufacturing facility in 1917 on 150 acre farm at Steeles & Dufferin
- Dr. John Fitzgerald (Canadian Medical Hall of Fame) was the first director
- Historical Contributions Biologicals of Medical significance

Biologicals

- **✓** Antitoxins
- **√Insulin**
- **✓** Epinephrine
- ✓ Heparin
- **✓ Plasma Fractionation**

✓ Penicillin



Vaccines

- ✓ Pertussis vaccine
- ✓ Polio vaccine
- √Smallpox vaccine
- ✓ Acellular pertussis
- √ Combination vaccines
- ✓Influenza vaccine



1918-19: Influenza Pandemic

JOLLY'S DRUG REWS.

No Need To Catch Spanish "Flu"

Cutter's Respiratory Vaccine is a sure preventive.

We are completely sold out today but a very large supply is on the way.

It will come in serial doses and prophylactic syringe doses

To the Busy Doctors

· Telephone or telegraph your requirements and supplies will be forwarded to you immediately on arrival.

Jolly's Cash Drug Store

1821 SOUTH RAILWAY STREET, REGINA, BASK

Opp. Union Station

Enterprising pharmacists were soon advertising the new vaccines. (The Leader, Regina, Saskatchewan, October 31, 1918. Photo courtesy Saskatchewan Archives Board)

Widespread Ravages of Spanish Influenza and Consequent Diseases

In Montreal Alone There Are 20,000 Cases of Influenza and From All Points Come News TORDATO, OCTOBER 12 TORDATO of Its Spread.-In Halifax We

Have 500 Cases.


OTTANA Thadred are case of Five Hundred Cases MONTREAL, October 13 — Of Of Spanish Influenza soldiers in this district being freat distance when almost provide the soldiers in this district being freat affabre have been almost provided by the soldiers of the soldiers and the soldiers are soldiers and the soldiers are soldiers. WINNIPEG, October-13—A proc-latination practically suspends

Newspapers of the day carried alarming reports of the spread of the disease. (The Halifax Herald, October 14, 1918. Photo courtesy Public Archives of Nova Scotia)




1918-19 - Connaught Supplies an Influenza Vaccine to the Nation

- During the pandemic there were frantic efforts to identify the cause of the disease and hopefully prepare a vaccine that might prevent it.
- Scientists had first targeted a bacterium, B. influenza, as the cause of influenza in 1892 and then prepared a vaccine based on a variety of strains isolated from influenza cases.
- Working day and night in a cramped lab, a small team under the direction of Dr. R.D. Defries, supplied Connaught's influenza vaccine free of charge, to provincial health departments, hospitals, the military and other public health services across the country.



1918-19 - Connaught Supplies an Influenza Vaccine to the Nation

 Due to this unprecedented emergency,
Connaught made no claims for the effectiveness of the vaccine, but kept careful records so that it could be evaluated.




Connaught's efforts were greatly appreciated by provincial health departments, as well as by the newly established Department of National Health in Ottawa, its creation in 1919 directly attributed to the pandemic.



1943-46: Connaught & Modern Influenza Vaccine Development

- Modern understanding of influenza began in the early 1930's when the virus was first isolated and cultivated in chicken eggs.
- The virus is then inactivated with formaldehyde to make a vaccine.
- There are three main types of influenza virus, but with many strains that change from year to year.
- This variability means that the vaccine has to be modified every year in order to prevent influenza outbreaks





1957: Influenza Vaccine – Pandemic Preparations



The most serious influenza pandemic since 1918-19 was in 1957, sparking the emergency production of influenza vaccine at Connaught Laboratories on behalf of the federal and provincial governments in Canada

Chickens Help Doctors Fight 'Walkabout' Flu

1976: "Swine Flu" Pandemic Preparations

- Fears of another influenza pandemic developed in 1976.
- Fortunately this "Swine Flu" emergency did not materialize, although a large vaccine production and vaccination effort was launched in North America.



In Canada, Connaught Laboratories packaged bulk influenza vaccine supplied from a British manufacturer and conducted clinical trials that involved employee volunteers.




The History of Vaccine


Development

Man's First Vaccine


- ✓ Efficacy?
- ✓Safety?
- ✓ Delivery?
- ✓ Research Cost?
- **✓ Development Cost?**
- /Manufacturing?














sanofi pasteur Canada Ltd.



Major Contributions:

Eradication of Smallpox



"I appreciate only too well how many of the concepts in the execution of the smallpox program saw the first light of day over a glass of beer with Bob [Wilson] and Paul [Fenje].

What I don't recall is whether the ideas stemmed from Wilson or Fenje, so perhaps they are better attributed to Wilje (or should it be Fenson?)."

D.A. Henderson to P. Fenje, June 18, 1979

Dr Paul Fenje

Dr R. J Wilson


Plate 11.4. Members of the Seminar on Vaccine Production, at the final meeting from 28 to 30 March 1968, at the Wyeth Laboratories, Philadelphia, Pennsylvania, USA. Left to right, front row: P. Fenje (Canada), S.S. Marennikova (USSR), A.C. Hekker (Netherlands), J.H. Brown (USA), R.J. Wilson (Canada) and I. Arita (WHO); back row: F.M. McCarthy (USA), M.Z. Bierly (USA), H. Tint (USA), V.N. Milushin (USSR), A. Bernstein (USA), C. Kaplan (United Kingdom), D.A. Henderson (WHO), B.A. Rubin (USA) and A.K. Fontes (USA).


sanofi pasteur Canada Ltd.





Major Contributions:


Eradication of Smallpox











23

sanofi pasteur Canada Ltd.



Major Contributions:

Eradication of Polio





ector of the Connaught Medical Research Laboraes, Dr. Robert D. Defries grew up with the institution ch discovered Medium 199, the fluid in which polio s was grown, making possible the mass production Salk vaccine. Dr. Defries was in Ann Arbor yesterfor the announcements about the vaccine.



15112158



sanofi pasteur Canada Ltd.





Eradication of Polio






isteur

Vaccine manufacturing – Industrialization





General Vaccine Production



Cell Substrate

- □Viral vaccines need a cell substrate
- ■Validated vaccine approved cell bank
- ■2 to 3 years to validate
- ■1 month to grow cells to production level



Upstream Process – Growth Phase



The Room

- Sterile
- Hepa filtered air
- Pressure balance
- •Steam sterilization
- Sterile distilled water supply
- •Gowning procedures

Quality Regulations: Three levels of barrier to protect the product



Upstream Process Primary Recovery

Cell Disruption

- Mechanical
- Chemical

Clarification

- Centrifugation:
- Filtration:
- Chromatography





Downstream Process

Primary Objective:

- removal of impurities
- Maintain biological activity

Secondary Objective:

Clearance of adventitious agents

Inactivation

- Chemical or physical
- BPL, formaldehyde, heat





Formulation

- Dilution
- Adjuvant (eg adsorption to AIOH or AIPO₄)
- Stabilizers
- Preservatives
- Blending antigens
 - Polio trivalent = type 1 + type 2 + type 3
 - Pneumococcal polysaccharide = 23 serotypes
 - Meningococcal polysaccharide = 4 serotypes
 - Pneumococcal conjugate = 7 serotypes
 - Acellular Pertussis = 1 to 5 different antigens (PT, FHA, Pertactin, Fim2, Fim3)
- Combination Vaccines
 - MMR = 3 vaccines (Measles, Mumps, Rubella)
 - Pentacel = 5 vaccines





Filling & Packaging

Sterile filling

Liquid vaccines

Freeze dried vaccines

Physical Inspection

Labelling & Packaging

Storage

2-8°C

Frozen

Shipping

Cold Chain







Quality Control



- Identity
- Quantity (specific activity)
- Purity (quantification of contaminants)
- Characterization (size, structure, sequencing)
- Activity (Immunology testing, in vitro based system)
- Potency in relevant animal model (correlates of protection)
- Microbial sterility, pyrogenicity, toxicity, general safety, etc.



Acellular Pertussis and Combination vaccines

In 1997 sanofi pasteur introduced Pentacel™ an Acellular Pertussis combination Vaccine which contains:


- 5 component acellular pertussis
- Diphtheria
- Tetanus
- IPV
- Hib



The research, development & manufacturing for Pentacel™ combination is completely Canadian



5-Component Pertussis





Manufacturing today - Pentacel







Increasing Regulatory Requirements



U.S. Food and Drug Administration


CENTER FOR BIOLOGICS EVALUATION AND RESEARCH







Compliance Revolution A Paradigm Shift




R Van Exan - June 2008

New concept in cGMP

Now compliance requires:

- ■Demonstration of control and reproducibility of all systems and processes throughout the full manufacturing cycle.
- Dramatic increase in facilities investments, time, data and personnel



Impact of Increasing Regulatory Compliance on the Vaccine Industry

Lot Release

- Testing of every lot by manufacturer and regulator test discrepancies
- Lot Failures

Increased Regulatory Compliance

- increase production failures as regulations become more stringent
- reduced capacity
- increased production cost
- supply disruptions

Increased Regulatory Penalties

- FDA "team biologics"
- Large fines
- Plant closures



Impact of Increasing Regulatory Compliance on the Vaccine Industry

Process Improvements and Process Change


- Removal of materials of animal origin
- Removal of blood products
- Removal of Thimerosal
- Increased cost of production

Cold chain disruption

- Increased cold chain monitoring increased loss of shipments
- Increased cost of shipping




Removal of Thimerosal from DTaP vaccines





Timeline for Capacity Increase



The vaccines business of sanofi-aventis Group

Decision timeline for capacity increase

Impact of the Compliance Revolution

Increased Vaccine Production Costs

- Manufacturing Costs
- Quality Control and Quality Assurance Costs
- Manufacturing facility costs

Reduced Capacity


- WIP Losses
- Longer production cycles

Reduced Profitability

- Plant closures
- Companies leaving the industry



Global Vaccine Supply



Next.....

